NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee C meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 03 April 2024

**Location:** Via Zoom

## Attendees

Committee members present

1. Professor Stephen O’Brien (Chair) Present for all items
2. Dr Richard Nicholas (Vice Chair) Present for all items
3. Michael Chambers Present for all items
4. Dr Mark Corbett Present for all items
5. Dr Prithwiraj Das Present for all items
6. Dr David Foreman Present for all items
7. Dr Rob Forsyth Present for all items
8. Dr Pedro Saramago Goncalves Present for all items
9. Iain McGowan Present for all items
10. Ugochi Nwulu Present for all items
11. Stella O’Brien Present for all items
12. Dr Clare Offer Present for all items
13. Dr Kate Ren Present for all items
14. Professor Andrew Renehan Present for items 4.1.3 to 6.2.2
15. Elizabeth Thurgar Present for all items
16. Alan Thomas Present for all items
17. Richard Ballerand Present for all items

NICE staff (key players) present

Jacoline Bouvy, Programme Director Items 1 to 4.2.2 and 6.1 to 6.2.2

Linda Landells, Associate Director Items 1 to 4.2.2 and 6.1 to 6.2.2

Kate Moore, Project Manager Items 1 to 4.2.2 and 6.1 to 6.2.2

Adam Brooke, Heath Technology Assessment Adviser Items 1 to 4.2.2

Harsimran Sarpal, Heath Technology Assessment Analyst Items 1 to 4.2.2

Ian Watson, Associate Director Items 5.1 to 5.2.2

Carl Jackson, Project Manager Items 5.1 to 5.2.2

Michelle Green, Heath Technology Assessment Adviser Items 5.1 to 5.2.2

Emilene Coventry, Heath Technology Assessment Analyst Items 5.1 to 5.2.2

Claire Hawksworth, Heath Technology Assessment Adviser Items 6.1 to 6.2.2

Emma Bajela, Heath Technology Assessment Analyst Items 6.1 to 6.2.2

External assessment group representatives present

Archie Walters, BMJ Technology Assessment Group Items 1 to 4.2

Melina Vasileiou, BMJ Technology Assessment Group Items 1 to 4.2

Ed Wilson, PenTAG Items 5.1 to 5.2

Max Barnish, PenTAG Items 5.1 to 5.2

Nigel Armstrong, KSR Items 6.1 to 6.2

Mirre Scholte, KSR Items 6.1 to 6.2

Clinical, Patient & NHS England experts present

James Ferguson, Patient expert, nominated by LHON Society Items 1 to 4.2

Lily Mumford, Patient expert, nominated by LHON Society Items 1 to 4.2

Professor Marcela Votruba, Clinical expert, nominated by Royal College of Ophthalmologists Items 1 to 4.2

Professor Patrick Yu Wai Man, Clinical expert, nominated by Royal College of Ophthalmologists Items 1 to 4.2

Fiona Marley, NHS Commissioning expert, nominated by NHS England Items 1 to 4.2

Esther Beswick, Patient expert, nominated by Leukaemia Care Items 5.1 to 5.2

Charlotte Crowley, Patient expert, nominated by Leukaemia Care Items 5.1 to 5.2

Professor Philip Hawkins, Clinical expert, nominated by the National Amyloidosis Centre Items 6.1 to 6.2

Professor Perry Elliott, Clinical expert, nominated by Pfizer Items 6.1 to 6.2

Paul Pozzo, Patient expert, nominated by UK ATTR Amyloidosis Patients’ Association Items 6.1 to 6.2

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair, Dr Richard Nicholas welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Dr Alex Cale, Amit Parekh, Dr Arpit Srivastava, Dawn Cooper, Iftab Akram, John Hampson, Satish Venkateshan and Dr Steve Lloyd.

### News and announcements

* 1. The chair thanked those who volunteered to be on the committee.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 05 March 2024.

### Appraisal of Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547]

* 1. Part 1 – Open session
		1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Chiesi Limited.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta11288/documents).
		3. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dawn Cooper, Dr Rob Forsyth and Ugochi Nwulu.
	2. Part 2 – Closed session (company representatives, patient, clinical and NHS commissioning experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Idebenone for treating visual impairment in Leber’s hereditary optic neuropathy in people 12 years and over [ID547] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta11288)

### Appraisal of Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198]

* 1. Part 1 – Open session
		1. The chair, Dr Richard Nicholas welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Servier Laboratories Ltd.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta11167/documents)
		3. The Chair led a discussion of the consultation comments presented to the committee.
	2. Part 2 – Closed session (company representatives, patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation [ID6198] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta11167)

### Appraisal of Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]

* 1. Part 1 – Open session
		1. The chair, Prof. Steve O’Brien welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Pfizer.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here.](https://www.nice.org.uk/guidance/indevelopment/gid-ta11389/documents)
		3. The Chair led a discussion of the consultation comments presented to the committee.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: [Project information | Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327] | Guidance | NICE](https://www.nice.org.uk/guidance/indevelopment/gid-ta11389)

### Date of the next meeting

The next meeting of the Technology Appraisal Committee C will be held on Tuesday 07 May 2024 and will start promptly at 08:45am.